Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Tusamitamab ravtansine - Sanofi

Next Previous
Drug Profile

Tusamitamab ravtansine - Sanofi

Alternative Names: IBI-126; Maytansin-loaded anti-CEACAM5 mAb; SAR '701; SAR-408701

Latest Information Update: 30 Jun 2025

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator ImmunoGen
  • Developer Erasmus MC; Sanofi
  • Class Antineoplastics; Drug conjugates; Immunoconjugates; Maytansinoids; Monoclonal antibodies
  • Mechanism of Action Tubulin inhibitors; Tubulin polymerisation inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Breast cancer; Gastric cancer; Non-small cell lung cancer; Oesophageal cancer; Pancreatic cancer; Solid tumours

Most Recent Events

  • 25 Apr 2025 Pharmacodynamics data from a preclinical studies in Prostate cancer presented at the 116th Annual Meeting of the American Association for Cancer Research (AACR-2024)
  • 19 Jan 2025 Sanofi completes phase II CARMEN-BT01 trial in Breast cancer (Second-line therapy or greater, Late-stage disease, Metastatic disease) in USA, Argentina, Chile, Hungary, South Korea, Netherlands, Russia, Taiwan, Turkey, Spain (IV) (NCT04659603)
  • 19 Jan 2025 Sanofi completes phase II CARMEN-BT01 trial in Pancreatic cancer (Second-line therapy or greater, Late-stage disease, Metastatic disease) in USA, Argentina, Chile, Hungary, South Korea, Netherlands, Russia, Taiwan, Turkey, Spain (IV) (NCT04659603)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top